AR and neoplasm: Through in silico screening, we identified a pharmacological inhibitor that binds to the HSP60 apical domain, disrupts HSP60 and ClpP interactions, triggers potent mitochondrial stress, induces robust PCa cell death in vitro, and inhibits tumor growth in vivo irrespective of androgen receptor (AR) status.